BD Launches First All-in-One Central Line Insertion System to Enhance Patient Safety
核心洞察
BD (搜索) commercially launched the CentroVena One (搜索)™ Insertion System, the first all-in-one central venous catheter insertion device designed to simplify central line placement for clinicians.
The system reduces procedural steps by 30% and insertion time by 50% compared to traditional methods, while minimizing contamination risk and insertion-related complications.
The device received FDA 510(k) clearance and was accepted into the FDA Safer Technologies Program, marking BD (搜索)'s entry into the acute CVC market.
BD (搜索) (Becton, Dickinson and Company) has commercially launched the BD® CentroVena One (搜索)™ Insertion System, marking what the company describes as "the most meaningful advancement in central line insertion since the technique was first introduced nearly seven decades ago." The first all-in-one central venous catheter (CVC) insertion device on the market is designed to simplify central line placement for clinicians and enhance patient safety in high-pressure acute care settings.
Addressing Critical Clinical Challenges
Central line insertion is performed millions of times annually in the U.S., yet the traditional process remains complex and fraught with risks. The conventional approach requires multiple component exchanges that can introduce contamination, create workflow delays, and increase the risk of serious complications including pneumothorax (搜索), arterial injury (搜索), air or guidewire embolism (搜索), bloodstream infections (搜索), and needlestick injuries (搜索).
"Central line placement is one of the highest-pressure bedside procedures our teams perform – especially in fast-moving, high-acuity environments where unpredictability is inherent and skilled clinicians must bring precision to complexity in real time," said Anthony Frank, MD, MBA, FACEP, chief medical officer and senior vice president of Medical Affairs at UNC Health Blue Ridge (搜索), one of the first health systems to pilot the system.
Streamlined Design and Performance Benefits
The CentroVena One (搜索)™ system consolidates essential components – including the introducer needle, syringe, guidewire, and catheter – into a single integrated platform. According to BD (搜索)'s data from a head-to-head simulation study published in The Journal of Emergency Medicine, this innovative approach delivers significant performance improvements compared to traditional CVC insertion methods:
- Simplifies workflow with 30% fewer steps
- Reduces insertion time by 50%
- Reduces contamination risk by minimizing touchpoints during catheter insertion
- Helps protect against insertion-related complications
The system incorporates several safety-focused design elements, including a pre-loaded kink-resistant guidewire, an integrated drape clip permanently attached to the guidewire to prevent guidewire embolism (搜索), and a pre-loaded catheter with self-dilating tip that eliminates the need for a separate dilation step. The introducer needle features integrated passive needle safety to reduce needlestick injury risk, while the closed insertion system is designed to minimize air embolism (搜索), clinician blood exposure, and patient blood loss.
Regulatory Recognition and Clinical Implementation
The CentroVena One (搜索)™ Insertion System received U.S. FDA 510(k) clearance and was accepted into the FDA Safer Technologies Program (STeP) for Medical Devices, a prestigious recognition reserved for substantial safety innovations. This regulatory milestone underscores the device's potential to address critical safety concerns in central line insertion.
"What stands out in our early experience with CentroVena One (搜索)™ is its intentional design around real-world clinical challenges – streamlining catheter placement while reducing opportunities for error, sterile field breaches and overall workload," Frank noted. "Innovations that better support frontline teams in this way align directly with our commitment to patient safety, high-quality care and infection prevention."
Market Impact and Strategic Positioning
The commercial launch represents BD (搜索)'s entry into the acute CVC market and expands the company's vascular access portfolio. As the global leader in vascular access solutions, BD aims to advance the standard of care for IV therapy by reducing vascular access-related complications, improving clinical and economic outcomes, and supporting healthcare facilities' vision of a "one-stick patient experience."
"By reducing procedural steps, helping protect against preventable complications and simplifying one of the most stressful procedures clinicians perform, we're supporting safer, faster care for patients when every second counts," said Ron Silverman, executive vice president and chief medical officer at BD (搜索).
The CentroVena One (搜索)™ system is now commercially available in the United States, marking a significant advancement in vascular access technology for acute care settings.